By Fineline Cube Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, SHA: 600196, HKG: 2196) announced that HLX97, a first-in-class small molecule inhibitor of lysine acetyltransferase 6A/B (KAT6A/B), has received Phase I clinical trial approval from China’s National Medical Products Administration (NMPA) for the treatment of advanced/metastatic solid tumors. The candidate represents a novel epigenetic target with no approved inhibitors globally, positioning Fosun Pharma at the forefront of KAT6A/B drug development.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Phase I clinical trial authorization |
| Product | HLX97 (small molecule) |
| Target | KAT6A/B (lysine acetyltransferase 6A/B) |
| Indication | Advanced/metastatic solid tumors |
| Developer | Fosun Pharma (SHA: 600196, HKG: 2196) |
| Approval Date | 6 Mar 2026 |
| Global Status | No KAT6A/B inhibitor approved worldwide |
Drug Profile & Mechanism
| Attribute | HLX97 Profile |
|---|---|
| Drug Class | Small molecule epigenetic modulator |
| Molecular Target | KAT6A and KAT6B (histone acetyltransferases) |
| Mechanism | Inhibition of KAT6A/B-mediated histone acetylation; disruption of oncogenic transcriptional programs |
| Therapeutic Area | Oncology (solid tumors) |
| Development Status | Phase I-ready; first-in-class globally |
| Competitive Position | No approved competitors; potential first-mover advantage in epigenetic space |
Scientific Rationale:
- KAT6A/B overexpression linked to multiple solid tumor types (breast, prostate, lung)
- Epigenetic modulation offers alternative to kinase-driven oncology paradigms
- Preclinical data suggests synthetic lethality opportunities with existing therapies
Strategic Context
| Factor | Implication |
|---|---|
| First-in-Class Status | HLX97 advances Fosun Pharma into novel target space beyond biosimilars and generics |
| Global Opportunity | NMPA approval enables China-first development; potential for U.S./EU IND submission based on Phase I data |
| Epigenetic Pipeline | Complements Fosun’s existing oncology portfolio (PD-1, ADCs) with differentiated mechanism |
| Investor Impact | SHA: 600196 / HKG: 2196 shares may benefit from innovation pipeline validation |
Development Outlook
- Phase I Design: Dose-escalation study in advanced solid tumor patients with KAT6A/B biomarker enrichment
- Biomarker Strategy: Companion diagnostic development for KAT6A amplification/overexpression
- Combination Potential: Preclinical exploration with immunotherapy and targeted agents
- Regulatory Pathway: China Phase I data to support global expansion; Breakthrough Therapy designation potential
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, first-in-class positioning, and commercial potential for HLX97. Actual results may differ due to trial outcomes, competitive dynamics in epigenetic drug development, and regulatory requirements.-Fineline Info & Tech